ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 431

Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy

Maria Greenwald1, Joann Ball2 and Harold Paulus3, 1Desert Medical Advances, PALM DESERT, CA, 2rheumatology, Desert Medical Advaces, Palm Desert, CA, 3Rheumatology, UCLA, Los Angeles, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: diagnosis, joint damage and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

 

Background/Purpose: Joint dermal temperature (temp) measured in less than a minute can identify specifically the individual RA patient most likely to develop radiographic change on Sharp Score in the next year. There is great debate regarding which patients should be treated with expensive therapies for rheumatoid arthritis (RA). Certain subsets of RA patients are more likely to cripple, such as sero-positive disease, those earlier in disease onset, and earlier age at onset, and higher inflammatory non-specific markers (like amyloid, fibrinogen). However, can we identify a specific patient at most risk for radiographic changes. We evaluated the power of touch to determine disease. It has long been noted in the literature that skin over a gout joint is “hot”, which we define as a temp equal to or above central temp. Elevated skin temps occur also over septic joints and RA. The hot joint will identify which individual is destined for new xray erosions.

Methods: A digital clinic dermal thermometer was used to record vital signs, both at skin on the forehead and over any painful joint, most often the wrist. The dermal temp can be measured accurately and in less than a minute (accuracy ±0.1 F). Sequentially 208 sero-positive RA patients on MTX (15-25 mg/week) and with baseline plus one year follow up hand/feet xrays were enrolled. No biologic therapy was permitted. Xrays were scored by a single reader (MG) with a modified van der Heijde total Sharp score (mTSS) without sequence order or identifiers. Medical history, WESR, CRP, baseline medications and xray were performed at screening. A small group of subjects without RA (n=25) were used as controls to evaluate the usual range of joint temp. 

Results: The dermal temp at a wrist of normal persons without RA is -12.0±4.6 F. The “hot” joint RA group had a joint temp in excess of central temp +1.06±0.69 (CI 0.23) and neared a 4-fold higher individual risk of new erosions compared to those RA “cool” joints.  Results were highly significant, p<0.001. Sensitivity for joint temp predicting erosions is 91.7% and specificity for joint temp predicting erosions 78%. Newer onset of RA, younger age, and WESR were mildly significant (P<0.05) but had poor specificity and sensitivity.

Conclusion:   A simple dermal temperature taken with a standard digital thermometer can quickly and accurately identify RA patients who are at high risk for further destructive change on MTX alone.  This can be submitted to insurers, national health registries, and provides objective data to what we have known for centuries, that the human hand can detect active disease.

 


Disclosure:

M. Greenwald,
None;

J. Ball,
None;

H. Paulus,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-dermal-temperature-specifically-identifies-the-individual-ra-patient-most-likely-to-develop-radiographic-change-on-sharp-score-an-exam-in-less-than-a-minute-can-predict-who-specifically-needs-b/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology